In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Stephen J. Freedland, MD, about the role of diet and nutrition in prostate cancer risk and outcomes. The phase 2 study is ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...

In this interview, Parviz K. Kavoussi, MD, discusses his diagnostic work-up for patients who present with chronic testicular pain and describes conservative and surgical management approaches for the ...

In this interview, Seth P. Lerner, MD, discusses current recommendations for managing patients during the BCG shortage, what the FDA is doing to resolve the problem, and a SWOG trial testing a new ...

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.

mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably. Both conditions involve the presence of metastases and sensitivity to ...

"Therapeutic strategies are needed in the management of NMIBC that recurs after gold-standard intravesical BCG," Gomella writes. Non–muscle invasive bladder cancer (NMIBC) often responds to induction ...

LiSWT and PRP independently and combined significantly improved IIEF scores in ED treatment compared to control therapy. LiSWT was the most effective standalone treatment, with a mean IIEF score ...

Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...